EVOMMUNE INC (EVMN)
Health Care · biotechnology · NYSE
Evommune is a clinical-stage biotech focused on developing innovative oral and injectable therapies to address unmet needs in chronic inflammatory diseases like atopic dermatitis and migraine.
What EVOMMUNE INC does
Evommune is a clinical-stage biotechnology company developing small molecule and protein-based therapies for chronic inflammatory diseases. Its primary product candidates include EVO756, an oral MRGPRX2 antagonist for atopic dermatitis and migraine, and EVO301, an injectable IL-18 binding protein fusion protein for atopic dermatitis and other inflammatory conditions.
Recent developments
In June 2026, the company discontinued the development of EVO756 for chronic spontaneous urticaria (CSU) after the drug failed to meet primary endpoints in a Phase 2b trial. The company has since pivoted focus for EVO756 toward atopic dermatitis and migraine, with Phase 2b data for AD expected in September 2026 and Phase 2b data for migraine expected in 2027.
From EVOMMUNE INC's filing of 2026-08-06.
Themes: chronic inflammation, atopic dermatitis, migraine prophylaxis, MRGPRX2 antagonist, IL-18 inhibition, clinical-stage biotech
Fundamentals
- Price$5.38 as of 2026-10-20 close
- Market cap$195M as of 2026-08-04 (share count; price 2026-10-20)
- P/En/a negative earnings
- Net margin-529.8% FY2025, SEC XBRL
- ROE-33.5% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+85.7% FY2025, SEC XBRL
- Beta1.03 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How EVMN compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $0 | -$35M | -$32M | -$0.89 | -$20M† | $183000† |
| Q1 FY2026 2026-03-31 | $0 | -$24M | -$22M | -$0.64 | -$28M | $83000 |
| Q4 FY2025 2025-12-31 | — | -$30M† | -$28M† | $15.14† | -$17M† | $104000† |
| Q3 FY2025 2025-09-30 | $10M | -$13M | -$12M | -$8.07 | -$10M† | $131000† |
| Q2 FY2025 2025-06-30 | $0 | -$23M | -$14M | -$8.80 | -$26M† | $0† |
| Q1 FY2025 2025-03-31 | $3M | -$15M | -$15M | -$9.48 | -$24M | $0 |
| Q4 FY2024 2024-12-31 | — | -$21M† | -$21M† | -$14.60† | -$19M† | $0† |
| Q3 FY2024 2024-09-30 | — | -$17M | -$16M | -$10.47 | — | — |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$60M
- Short-term investments$141M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How EVOMMUNE INC looks technically
EVOMMUNE INC (EVMN) is trading 70.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average has held below its 200-day average for at least 30 trading days — a long-sustained "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 60, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 21, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 3 trading days ago. Trading volume is unusually light — only about 40% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 70.2% below its 200-day average, the long-term trend line — a long-term downtrend | -70.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.16 | $10.16 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $18.06 | $18.06 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 62 calendar days ago — the swings before that are what the structure reading is measured on | 62 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 15.06. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average has held below its 200-day average for at least 30 trading days — a long-sustained "death cross", a bearish long-term signal | at least 30 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 60, with sellers in control | 59.7 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 21, in oversold territory (below 30) | 21.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($5.09 to $8.30) — its "stochastic" reading is 9 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 9.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $33.20 (set on 2026-02-10) | $33.20 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $5.09 (set on 2026-10-16) | $5.09 |
| Above the all-time low | it is 5.7% above its all-time low | +5.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months) | 84th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5312 between its high and its low — about 9.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5312 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.43 and $9.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.43 – $6.84 – $9.25 |
| Typical daily range (% of price) | its price moves about 9.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.9% |
| Stretch from the 200-day average | it is trading 23.9 daily ranges below its 200-day average price (70.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 23.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 40% of its 30-day average | 0.40× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 7.4% since the prior reading | -7.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.11 toward sell |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.6% below the previous close 6 sessions ago and has not traded back through the level it left behind at 6.25 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.6% |
| Gap filled | a 2.5% gap up opened on 2026-10-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.06% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 45.2 percentage points (the stock lost 44.2% while the market gained 1.0%) | -45.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 57.0 percentage points (the stock lost 53.3% while the market gained 3.6%) | -57.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 89.3 percentage points (the stock lost 80.8% while the market gained 8.5%) | -89.3% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 56% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 8.0% of the share price. | -56.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 70% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $17.65 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -69.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 44% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $9.55 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -43.7% |
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $15.06.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $15.06.
This reading has stood for 39 trading days, since 2026-08-26.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Oversold (14-day RSI below 30) · Broke down to a new 20-day low · MACD just crossed bullish (12/26/9) · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.83 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$22.33 range $8.00 – $30.00; median $22.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EVMN
- Consensus EPS estimate-$0.8347 next reporting period, as of 2026-10-15
- Estimate change, 30 days-$0.0087 from -$0.826, on 2026-09-10, 35-day window
- Readings revised upward29% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has no approved products, has incurred significant operating losses since inception, and will require substantial additional capital to fund operations.","Failure to successfully complete clinical trials or achieve primary endpoints, as seen with the recent discontinuation of the CSU program for EVO756, could materially harm the business.","The use of artificial intelligence in business operations and drug development is subject to evolving global regulations and compliance risks."]
What changed in the latest 10-Q
AI-assisted comparison of EVMN's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- In June 2026, announced top-line results from the Phase 2b trial evaluating EVO756 in adults with moderate-to-severe CSU; the trial did not meet its primary endpoint of mean change in UAS7 at 12 weeks at any dose, and the company decided to cease development of EVO756 for CSU.
- Stated the company is continuing to evaluate EVO756 in additional indications in which neuroinflammation and mast cell degranulation are key drivers of disease.
- Stated the Phase 2b dose-ranging trial of EVO756 in moderate-to-severe AD was initiated in August 2025, and the company expects to report initial results in September 2026.
- Added that a Phase 2b trial of EVO756 in migraine prophylaxis was initiated in July 2026, with initial results expected in 2027.
- Added detailed description of the EVO756 migraine Phase 2b trial: global randomized, double-blind, placebo-controlled dose-ranging trial in adults with refractory migraine experiencing ≥6 migraine days per month; approximately 330 patients randomized across two active dose arms and placebo for 12 weeks; exploring daily doses of up to 100 mg; primary endpoint is mean change from baseline in monthly migraine days (MMD); key secondary endpoints include proportion of patients achieving ≥50% and ≥75% reductions in MMD, change from baseline in monthly headache days and monthly acute migraine medication use.
- Updated accumulated deficit as of June 30, 2026: $275.0 million.
- Removed:
- Removed statement that EVO756 was initially being developed for CSU, AD and migraine (replaced with AD and migraine only after cessation of CSU development).
- Removed statement that a Phase 2b dose-ranging trial in CSU was initiated in April 2025 with initial results expected in June 2026.
- Removed statement that EVO756 Phase 2b AD initial results were expected in the third quarter of 2026 (now specified as September 2026).
- Removed statement that a migraine Phase 2b trial was planned to initiate in mid-2026; replaced with actual initiation in July 2026.
- Removed accumulated deficit figure as of March 31, 2026: $242.8 million.
- Reworded:
- Changed description of EVO756 indications from 'initially developing EVO756 for the treatment of CSU, AD and migraine' to 'developing EVO756 for the treatment of AD and migraine'.
- Changed AD Phase 2b initial results timing from 'third quarter of 2026' to 'September 2026'.
- Changed migraine trial timing from planned initiation 'mid-2026' (older) to actual initiation 'July 2026' (newer).
- Updated accumulated deficit figure from $242.8 million (March 31, 2026) to $275.0 million (June 30, 2026).
- Notes:
- The newer text is truncated at 'have not generated any approved' and the older text is truncated at 'Any failure to raise', so only the portion of the MD&A included in the provided excerpts was compared.
- Only factual changes are reported; no materiality or investment conclusions are drawn.
Risk Factors
- Added:
- The newer filing (filed 2026-08-06) adds the clause 'except as set forth below' to the sentence stating there have been no material changes to risk factors since the Annual Report.
- The newer filing (filed 2026-08-06) adds a new risk factor heading, 'Our use and provision of AI-powered solutions could lead to operational or reputational damage, competitive harm, legal and regulatory risk and additional costs.'
- The newer filing (filed 2026-08-06) adds three paragraphs under the new AI risk factor discussing employee use of AI technologies, potential regulatory laws (including EU AI Act, Colorado Artificial Intelligence Act, California Bot Disclosure Law, Utah Artificial Intelligence Policy Act, CCPA regulations), potential EU AI Act fines ('up to €35 million or 7% of a company's total worldwide annual turnover for the preceding financial year, whichever is higher'), compliance costs, potential competitive disadvantages, risk of unintended outputs, and risk of sensitive information leakage.
- Reworded:
- The newer filing (filed 2026-08-06) changes the header of Item 2 from 'Unregistered Sales of Equity Securities.' to 'Unregistered Sales of Equity Securities and Use of Proceeds.'
- The newer filing (filed 2026-08-06) changes the Rule 10b5-1 trading plans period reference from 'fiscal quarter ended March 31, 2026' to 'fiscal quarter ended June 30, 2026'.
- The newer filing (filed 2026-08-06) replaces the entire trading arrangement table: the older filing (filed 2026-05-07) lists seven adoption entries with one column labeled 'Date'/'Expiration Date', while the newer filing lists a single termination entry for Eugene Bauer with an 'Action' of 'Termination', an effective date of May 28, 2026, and columns renamed to 'Effective Date'/'Scheduled Expiration Date'.
- The newer filing (filed 2026-08-06) changes the phrase 'as each term is defined in item 408(a) of Regulation S-K' to 'as each term is defined in Item 408(c) of Regulation S-K'.
- The newer filing (filed 2026-08-06) changes the period reference in the sentence about director/officer adoptions or terminations from 'during the three months ended March 31, 2026' to 'during the three months ended June 30, 2026'.
- Notes:
- The provided texts include content beyond the Risk Factors section (Items 2–6, signature pages), so some reported changes fall outside the Risk Factors section strictly speaking.
- The older filing's signature page appears to be included while the newer filing's signature page is truncated at 'Pursuant to the requirements of', which could affect comparability of that portion.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-162 buys ($146260) · 9 sells ($2M) — 2 buying, 6 selling insiders
Most recent open-market transaction: 2026-07-08. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EVMN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding EVMN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,276,066
- Reported value $16,958,918
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about EVMN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
EVMN had 2,892,407 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
EVMN had 7.97% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.86 days to cover at the same settlement.
- Reported short interest (shares) 2,892,407
- Short interest (% of shares outstanding) 7.97%
- Prior settlement (shares) 2,876,209
- Reported change 0.56%
- Days to cover (reported) 3.86
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Sanofi (SNY)
- Eli Lilly (LLY)
- AbbVie (ABBV)
- Amgen (AMGN)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EVMN vs…
EVOMMUNE INC is found in…
Frequently asked questions
What does EVOMMUNE INC (EVMN) do?
Evommune is a clinical-stage biotechnology company developing small molecule and protein-based therapies for chronic inflammatory diseases. Its primary product candidates include EVO756, an oral MRGPRX2 antagonist for atopic dermatitis and migraine, and EVO301, an injectable IL-18 binding protein fusion protein for atopic dermatitis and other inflammatory conditions.
What sector is EVOMMUNE INC (EVMN) in?
EVOMMUNE INC (EVMN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NYSE.
Who are EVOMMUNE INC's (EVMN) competitors?
Notable peers of EVOMMUNE INC (EVMN) include Regeneron Pharmaceuticals, Sanofi, Eli Lilly, AbbVie and Amgen. This peer set is informational only — not financial advice.
Is EVOMMUNE INC (EVMN) overbought or oversold right now?
EVOMMUNE INC (EVMN) is currently in oversold territory (its 14-day RSI is 21, below 30) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EVMN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.